About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDNCT04267016

Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care

This is an observational study in renal transplant recipients to evaluate the acceptability, feasibility, and clinical utility of TruGraf® testing in conjunction with standard clinical assessment. Tru...

Lead sponsor: Transplant Genomics, Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Transplant Genomics, Inc.

Collaborators

Duke University

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Recipient of a primary or subsequent deceased-donor or living donor kidney transplantation.
•Stable serum creatinine (current serum creatinine \<2.3 mg/dl, \<20% increase compared to the average of the previous 3 serum creatinine levels)
•Kidney transplant patients who \>90 days (+/- 2 weeks) post-transplant will be included in this study

Exclusion Criteria

•Need for combined organ transplantation with an extra-renal organ and/or islet cell transplant.
•Recipients of previous non-renal solid organ and/or islet cell transplantation.
•Infection with HIV.
•Infection with BK nephropathy.
•Patients that have nephrotic proteinuria (urine protein \>3 gm/day).

Related studies

RECRUITINGPhase 2/3

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

NCT07412470 · Kidney Transplant Rejection

Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA

NCT07415876 · Kidney Transplant Rejection

Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

NCT07006532 · Kidney Transplant Rejection

Platelet Aggregation in the Diagnosis of Acute Graft Rejection

NCT07275541 · Platelet Aggregation, Kidney Transplant Rejection

Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring

NCT07060716 · Kidney Transplant Rejection, Cell-free DNA

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: September 28, 2021Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment26

Start dateAug 2020

Last updatedSep 28, 2021

Condition

Kidney Transplant Rejection

Locations shown

Duke University

Durham, North Carolina

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 28, 2021Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions